2002.12 Anhui Biochem Pharm Co., Ltd. is established

2003.03 Creation of R&D team to research and develop APIs for Anti-HIV/AIDS products using chiral synthetic technology 

2006.05 Honored by Bureau of Science and Technology of Anhui Province for superior Hi-Tech enterprise and CME synthetic process route

2006.07 Honored by all provincial banks for Credible Company and AAA Grade rating

2007.03 Lamivudine DMF number granted by US FDA (DMF No.20468)

2007.04 Honored by Anhui Development and Reform Commission for Key Project and 861 Project Enterprise

2007.05 Memorandum of Understanding signed with the Clinton Foundation HIV/AIDS Initiative(USA)

2007.06 Signed agreement with QVT Fund LP (UK) for USD $10 million capital investment

2007.09 API manufacturing base at Anhui Taihe Industrial Park established

2007.12 Name changed to Anhui Biochem United Pharmaceutical Co., Ltd. from Anhui Biochem Pharma Co., Ltd.

2008.04 Creation of Anhui Biochem (Bio-Pharma) Co., Ltd. for manufacturing finished pharmaceutical products (from the acquisiton of a bio-pharmaceutical company)

2008.05 Lamivudine API approved by Health Canada (DMF No.2008-036)

2008.08 China SFDA grants GMP approval for API manufacturing facility with GMP certificate

2008.08 Honored by Bureau of Science and Technology of Anhui Province for significant advancement in Science and Technology

2008.09 GMP application from Anhui Biochem (Bio-Pharma) Co., Ltd. is in process by China SFDA

2008.10 Products registration in Russia is started

2008.10 China SFDA grants certificate of approval for manufacturing Entecavir API

2008.10 China SFDA grants GMP approval for Lafutidine API with GMP certificate (No.:Anhui J0253)

2008.12 Permitted to prepare for establishing a subsidiary: Anhui Biochem Medical Sales Co., Ltd.

2008.12 Ritonavir Workshop and Lopinavir Workshop have been put into production

2009.03 Anhui Biochem Medical Sales Co., Ltd. is inspected and approved by Anhui Food & Drug Administration

2009.03 China SFDA grants GMP approval for Lamivudine API with GMP certificate (No.: Anhui K0276)

2009.04 Lamivudine Tablet from Anhui Biochem (Bio-Pharma) Co., Ltd. passed the technical evaluation of China SFDA

2009.05 China SFDA grants Drug Approval (No.:H20090217) for Selegiline Hydrochloride Capsule from Anhui Biochem (Bio-Pharma) Co., Ltd.

2009.06 China SFDA grants GMP approval for Anhui Biochem (Bio-Pharma) Co., Ltd.